Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis

Tan, Qiaoyun; Liu, Shuxia; Liang, Caixia; Han, Xiaohong; Shi, Yuankai

doi:10.1111/1759-7714.12815

Cited by 41 publications

(35 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dynamics of NLR and ANC during nivolumab treatment may be associated with the efficacy of the subsequent salvage chemotherapy. Many studies have shown that low baseline NLR and ANC predict the efficacy of nivolumab therapy in various cancers . More recent studies have shown that an early decrease in NLR during treatment with PD‐1 inhibitors predicts its efficacy .…”

Section: Discussionmentioning

confidence: 99%

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

et al. 2018

View full text Add to dashboard Cite

Several recent studies have shown that salvage chemotherapy following PD‐1 blockade produces high antitumor activity in some patients with non‐small lung cancer (NSCLC). However, the underlying synergistic mechanisms remain uncertain. The blood neutrophil‐to‐lymphocyte ratio (NLR) and absolute neutrophil count (ANC) can reflect the number of circulating myeloid‐derived suppressor cells and tumor‐associated neutrophils. The immunosuppressive status of the tumor microenvironment could be monitored by the time‐series patterns of NLR and ANC. The dynamics of NLR and ANC during nivolumab treatment were retrospectively explored in 15 patients: 8 patients receiving subsequent salvage chemotherapy (2 groups: 3 non‐responders and 5 responders), and 7 responders to nivolumab alone (2 groups: 4 partial response and 3 complete response). The dynamics of NLR and ANC during nivolumab differed among these four groups (NLR P = 0.045, ANC P = 0.067). NLR and ANC during nivolumab treatment increased over time in non‐responders to salvage chemotherapy, with an inverse relationship between drug response and NLR or ANC at four to six weeks among the four groups. We hypothesize that the early dynamics of NLR and ANC during nivolumab may be associated with the late efficacy of subsequent salvage chemotherapy. Further studies involving a large cohort are needed to confirm these findings, which could provide insight into the role of myeloid immunosuppressor cells in combination PD‐1 blockade and chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…144 A recent meta-analysis of 17 studies showed that a raised pre-treatment NLR was associated with a 1.81 increased risk of progression and 2.26 increased risk of death across malignancies. 145 This could be attributed to neutrophilia/lymphopenia, indicating an intrinsically immune-tolerogenic microenvironment, and leading to inferior response rates and a poorer prognosis. Interestingly, a number of studies have shown a superior predictive ability of post-treatment rather than pre-treatment NLR in correlating with outcome, suggesting systemic inflammation to be a dynamic rather than static predictive correlate of treatment benefit.…”

Section: Molecularly Targeted Modulation Of Cancerrelated Inflammationmentioning

confidence: 99%

“…146,147 While PLR has also been linked to poorer OS and PFS in ICItreated patients, no significant difference was found in the context of the aforementioned meta-analysis, possibly because of the small number of relevant studies available. 145,148,149 Similarly, contradictory results have arisen when evaluating the predictive role of mGPS in the setting of ICI treatment. For instance, one study found that mGPS was superior to NLR and other inflammation-based scores in determining outcomes in NSCLC patients treated with nivolumab, while another study refuted such an association.…”

Section: Molecularly Targeted Modulation Of Cancerrelated Inflammationmentioning

confidence: 99%

“…In general, an elevated NLR has been associated with worse outcomes, with higher pre‐treatment scores being associated with poorer OS and PFS in patients treated with ICI for melanoma, non‐small cell lung cancer (NSCLC) and genitourinary cancers . A recent meta‐analysis of 17 studies showed that a raised pre‐treatment NLR was associated with a 1.81 increased risk of progression and 2.26 increased risk of death across malignancies . This could be attributed to neutrophilia/lymphopenia, indicating an intrinsically immune‐tolerogenic microenvironment, and leading to inferior response rates and a poorer prognosis.…”

Section: Introductionmentioning

confidence: 99%

“…While PLR has also been linked to poorer OS and PFS in ICI‐treated patients, no significant difference was found in the context of the aforementioned meta‐analysis, possibly because of the small number of relevant studies available . Similarly, contradictory results have arisen when evaluating the predictive role of mGPS in the setting of ICI treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

Sanghera

Teh

Pinato

2019

Liver International

View full text Add to dashboard Cite

The pathogenesis of hepatocellular carcinoma (HCC) strongly relates to inflammation, with chronic up‐regulation of pro‐inflammatory mediators standing as a potential unifying mechanism that underscores the origin and progression of HCC independent of aetiology. Activation of the diverse pro‐inflammatory mediators either within the tumour or its microenvironment is part of an active cross‐talk between the progressive HCC and the host, which is known to influence clinical outcomes including recurrence after radical treatments and long‐term survival. A number of clinical biomarkers to measure the severity of cancer‐related inflammation are now available, most of which emerge from routine blood parameters including neutrophil, lymphocyte, platelet counts, as well as albuminaemia and C‐reactive protein levels. In this review, we summarise the body of evidence supporting the biologic qualification of inflammation‐based scores in HCC and review their potential in facilitating the prognostic assessment and treatment allocation in the individual patient. We also discuss the evidence to suggest modulation of tumour‐promoting inflammation may act as a source of novel therapeutic strategies in liver cancer.

show abstract

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients

et al. 2020

View full text Add to dashboard Cite

Background There is increasing evidence that immunotherapy with nivolumab, an anti‐programmed death 1 monoclonal antibody, is effective in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the predictive role of hematological inflammatory markers such as neutrophil‐to‐lymphocyte ratio (NLR) and the modified Glasgow prognostic score (mGPS) in patients with R/M SCCHN treated with nivolumab remains unclear. Methods We conducted a multi‐institutional cohort study to evaluate the impact of pretreatment NLR and mGPS on overall survival (OS) and progression‐free survival (PFS) in patients with R/M SCCHN treated with nivolumab in Japan. From 2012 to 2013, 102 patients were eligible, of whom 88 were finally included in the analysis. mGPS was calculated as follows: mGPS of 0, C‐reactive protein (CRP) ≤1.0 mg/dL; 1, CRP > 1.0 mg/dL; and 2, CRP > 1.0 mg/dL and albumin < 3.5 mg/dL. Optimal cutoff point of dichotomized NLR was calculated using the area under the receiver operating characteristic curve (AUROC). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated by Cox proportional hazard models adjusted by potential confounders. Results Higher NLR was significantly associated with worse survival (1‐year OS: 45.3% vs 16.3%, log‐rank P ‐value < .001, adjusted HR: 4.40 (95% CIs: 1.78‐10.88); one‐year PFS: 39.1% vs 9.0%, P ‐value = .001, adjusted HR: 3.37 (95% CI: 1.64‐6.92)). In addition, high mGPS (=2) was significantly associated with worse survival compared to low mGPS (=0) (1‐year OS: 37.4% vs 26.1%, P ‐value = .004, adjusted HR: 4.20 (95% CI:1.54‐11.49); 1‐year PFS: 41.5% vs 24.8%, P ‐value = .007, adjusted HR: 2.01 (95% CI: 0.87‐4.68)). These associations were consistent with subgroup analyses stratified by potential confounders. Conclusions Pretreatment NLR and mGPS might be predictive markers of survival in patients with R/M SCCHN treated with nivolumab.

show abstract

Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis

Cited by 41 publications

References 45 publications

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients

Contact Info

Product

Resources

About